SUBSCRIBE
SUBSCRIBE

Humanetics

IN THE PRESS
BioMidwest
BIO 300 Pharmacokinetics Studies Published
July 27, 2022
 · 
2 min read
Drug Development
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
July 12, 2022
 · 
3 min read
BioMidwest
U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure
June 21, 2022
 · 
2 min read
Deals
Humanetics Acquires mg-sensor to Advance Its Safety, Digital and Sensor Vision
June 21, 2022
 · 
3 min read
BioMidwest
Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
May 18, 2022
 · 
3 min read
Business
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 9, 2022
 · 
4 min read
BioMidwest
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
January 13, 2022
 · 
3 min read
Business
Humanetics Corporation Adds Two New Experts to its Board
October 26, 2021
 · 
3 min read
Drug Development
Humanetics Corporation Announces Results from Phase 1 Trial of BIO 300 Oral Powder
September 22, 2021
 · 
3 min read
FDA
Humanetics Corporation’s BIO 300 Receives Fast Track Designation from FDA
August 24, 2021
 · 
2 min read
Load More
JOBS